NYU & Montreal Heart Instit. teaming on the COLCORONA study of Colchicine in early phase COVID-19 infx. TBD in 6,000 patients with mild forms of the disease. Dr. M Pillinger says colchicine, early on, may inhibit damaging inflammatory responses https://t.co/UTW2g6QU2r